ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

0P48 Moberg Pharma Ab (publ)

30.45
0.00 (0.00%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Moberg Pharma Ab (publ) LSE:0P48 London Ordinary Share SE0003613090 MOBERG PHARMA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 30.45 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Appointment of Chief Medical Officer at Moberg Pharma

30/07/2020 7:27am

PR Newswire (US)


Moberg Pharma Ab (publ) (LSE:0P48)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Moberg Pharma Ab (publ) Charts.

STOCKHOLM, July 30, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma. Dr Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH.

Moberg Pharma is pleased to announce the appointment of Dr Cindy Wong as Chief Medical Officer. Dr Wong brings extensive international experience in clinical development and registration of new products in a number of treatment areas including Dermatology. She has held positions as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH and Chief Medical Officer at Q-Med/Galderma, as well as senior positions at regulatory authorities in both Sweden and Australia. Dr Wong is board certified in internal medicine and clinical immunology. She is a medical graduate from the University of Adelaide and has completed postgraduate training in Internal Medicine, Clinical Immunology and Immunopathology.

"We look forward to welcoming Cindy to Moberg Pharma. She will be joining the company in a highly exciting stage as we recently completed phase 3-trials for MOB-015, where she will be adding valuable experience from the development, registration and commercialization of novel treatments", says Anna Ljung, CEO Moberg Pharma.

CONTACT:

For additional information, please contact:

Anna Ljung, CEO
telephone: +46-707-66-60-30
e-mail: anna.ljung@mobergpharma.se

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. CET on July 30th, 2020

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/appointment-of-chief-medical-officer-at-moberg-pharma,c3161115

The following files are available for download:

https://mb.cision.com/Main/1662/3161115/1284934.pdf

Appointment of Chief Medical Officer at Moberg Pharma

 

 

Cision View original content:http://www.prnewswire.com/news-releases/appointment-of-chief-medical-officer-at-moberg-pharma-301102807.html

SOURCE Moberg Pharma

Copyright 2020 PR Newswire

1 Year Moberg Pharma Ab (publ) Chart

1 Year Moberg Pharma Ab (publ) Chart

1 Month Moberg Pharma Ab (publ) Chart

1 Month Moberg Pharma Ab (publ) Chart

Your Recent History